SomaKit TOC is used to diagnos patients with GEP-NET, to find out whether the tumor overexpresses somatostatinreceptors or not, and to localizing primary tumours and their metastases. The kit is the first ever approved PET radiopharmaceutical kit.
The 68Ga-generators approved to use for reconstitution are GalliAd and GalliaPharm.
The national guidelines for GEP-NET in Sweden recommends that a Gallium-Dotatoc-PET shoud be performed when diagnosing GEP-NET’s.
After the radiolabelling process, the solution is indicated for PET imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NET) for localizing primary tumours and their metastases.
The mechanism of action
SomaKit TOC binds to somatostatin receptors. In vitro, this radiopharmaceutical binds with high affinity mainly to SSTR2 but also, to a lesser extent, to SSTR5.
The kit reduces the preparation time substantially as well as the time for quality control compared to the production of Ga-68 Dotatoc.
SomaKit TOC was approved by the European Medicines Agency in December 2016 and was placed on the Scandinavian market on the 1st of September 2017.
Fact about the product
Must be stored and transported in cold conditions (2°C to 8°C). After radiolabelling valid for 4 hours.
Information for HCP
Follow the link to your local SmPC
SomaKit TOC is manufactured by Advanced Accelerator Applications (AAA) and is distributed in the Nordic region by SAM Nordic.